TMCnet News

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
[November 17, 2017]

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit


The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Genocea Bioscience, Inc. (NASDAQ: GNCA) ("Genocea" or the "Company") securities during the period between May 5, 2017 and September 25, 2017, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until January 2, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Genocea securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses thedefendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that Genocea's finances were insufficient to support Phase 3 trials of GEN-003.



According to the complaint, following the September 25, 2017 announcement that the Company was halting spending and activities on GEN-003, exploring strategic alternatives for the drug, and cutting 40% of its workforce, the value of Genocea shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Genocea securities purchased on or after May 5, 2017 and September 25, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.


Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.


[ Back To TMCnet.com's Homepage ]